Can D-Dimer Detects Snake Venom Induced Blood Clotting?
Researchers want to assess the accuracy and marginal value of D-dimer in detecting venom-induced consumption coagulopathy (VICC) in a new study.
Source: medindia.net
Page 3 - Diagnostic Performance News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Diagnostic Performance. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Diagnostic Performance Today - Breaking & Trending Today
Blue Earth Diagnostics Completes Patient Accrual in Phase 3 REVELATE Clinical Trial of 18F-Fluciclovine PET Imaging for Detection of Recurrent Brain Metastases
- Clinical utility of 18F-fluciclovine being investigated in expanded areas of cancer imaging - Blue Earth Diagnostics, a Bracco company and recognized leader in the development and commercialization
Source: finanznachrichten.de
Blue Earth Diagnostics Announces Dosing of Initial Patient in Phase 3 REVELATE Clinical Trial of 18F-Fluciclovine PET Imaging for Detection of Recurrent Brain Metastases
Blue Earth Diagnostics Announces Dosing of Initial Patient in Phase 3 REVELATE Clinical Trial of 18F-Fluciclovine PET Imaging for Detection of Recurrent Brain Metastases Clinical utility of Axumin (fluciclovine F 18) being investigated in expanded areas of cancer imaging Getty Images January 18, 2021 — Blue Earth Diagnostics, a Bracco company and recognized leader in the development and commercialization of innovative PET radiopharmaceuticals, today announced that the first patient has been dosed in its Phase 3 REVELATE clinical trial of 18F-fluciclovine, a positron emission tomography...
Source: itnonline.com
Blue Earth Diagnostics Announces Dosing of Initial Patient in Phase 3 REVELATE Clinical Trial of 18F-Fluciclovine PET Imaging for Detection of Recurrent Brain Metastases
(1) - Clinical utility of Axumin (fluciclovine F 18) being investigated in expanded areas of cancer imaging - Blue Earth Diagnostics, a Bracco company and recognized leader in the development and commercialization of innovative PET radiopharmaceuticals, today announced that the first patient has been dosed in its Phase 3 REVELATE clinical trial of 18F-fluciclovine, a positron emission tomography (PET) imaging radiopharmaceutical being studied for potential use in detecting recurrent brain metastases. The REVELATE study is a Phase 3, multi-center, single-arm imaging study being conducted in t...
Source: finanznachrichten.de